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Summary We examined the cytotoxicity and biochemical effects of the lipophilic antifol trimetrexate (TMQ)
in two human colon carcinoma cell lines, SNU-C4 and NCI-H630, with different inherent sensitivity to TMQ.
While a 24 h exposure to 0.1 M TMQ inhibited cell growth by 50-60% in both cell lines, it did not reduce
clonogenic survival. A 24 h exposure to 1 and 10 ILM TMQ produced 42% and 50% lethality in C4 cells, but
did not affect H630 cells. Dihydrofolate reductase (DHFR) and thymidylate synthase were quantitatively and
qualitatively similar in both lines. During drug exposure, DHFR catalytic activity was inhibited by > 85% in
both cell lines; in addition, the reduction in apparent free DHFR binding capacity (,<20% of control),
depletion of dTTP, ATP and GTP pools and inhibition of [6-3H]deoxyuridine incorporation into DNA were
similar in C4 and H630 cells. TMQ produced a more striking alteration of the pH step alkaline elution profile
of newly synthesised DNA in C4 cells compared with 630 cells, however, indicating greater interference with
DNA chain elongation or more extensive DNA damage. When TMQ was removed after a 24 h exposure to
0.1 tM, recovery of DHFR catalytic activity and apparent free DHFR binding sites was evident over the next
24-48 h in both cell lines. With 1 and 10 JAM, however, persistent inhibition of DHFR was evident in C4 cells,
whereas DHFR recovered in H630 cells. These data suggest that, although DHFR inhibition during TMQ
exposure produced growth inhibition, DHFR catalytic activity 48 h after drug removal was a more accurate
predictor of lethality in these two cell lines. Several factors appeared to influence the duration of DHFR
inhibition after drug removal, including initial TMQ concentration, declining cytosolic TMQ levels after drug
removal, the ability to acutely increase total DHFR content and the extent of TMQ-mediated DNA damage.
The greater sensitivity of C4 cells to TMQ-associated lethality may be attributed to the greater extent of
TMQ-mediated DNA damage and more prolonged duration of DHFR inhibition after drug exposure.
Methotrexate, a 'classical' antifol, has been useful in the
treatment of human neoplasms including acute lymphocytic
leukaemia, non-Hodgkin's lymphoma, osteosarcoma, breast
cancer and squamous cell carcinoma of the head and neck.
Methotrexate is clinically inactive, however, against several
human solid tumours, including colorectal carcinoma. Resis-
tance to methotrexate has been attributed to numerous
mechanisms (Allegra, 1990), including impaired membrane
transport (Assaraf & Schimke, 1987; Schuetz et al., 1988),
defective polyglutamation (Cowan & Jolivet, 1984; Pizzorno
et al., 1988), reduced affinity of the target enzyme dihydro-
folate reductase (EC 1.5.1.3, DHFR) (Jackson et al., 1980;
Melera et al., 1987), increase in total DHFR activity due to
gene amplification (Kaufman & Schimke, 1981; Cowan et al.,
1982; Domin et al., 1983), decreased levels of thymidylate
synthase (EC 2.1.1.45, TS) (White & Goldman, 1981; Curt et
al., 1985) and thymidine (dThd) salvage (Van Mouwerik et
al., 1987).
'Non-classical' antifols have been developed in an effort to
overcome potential mechanisms of resistance. Trimetrexate
(TMQ) is a 2,4-diaminoquinazoline antifol that is undergoing
clinical evaluation as an antineoplastic agent and has been
approved for the treatment of AIDS-related Pneumocystis
carinii infection. Unlike methotrexate, TMQ is lipophilic and
enters the cell by a transport process distinct from the
reduced folate carrier (Diddens et al., 1983; Jackson et al.,
1984; Kamen et al., 1984). TMQ is a direct, potent inhibitor
of DHFR, and does not undergo polyglutamation. In pre-
clinical models, TMQ is active against several murine solid
tumours which are refractory to methotrexate (Lin & Ber-
tino, 1987). Cells which are resistant to methotrexate on the
basis of impaired membrane transport are sensitive to TMQ
(Mini et al., 1985; Van Der Veer et al., 1989). Multidrug-
resistant (MDR) cell lines are cross-resistant to TMQ;
verapamil enhances TMQ cytotoxicity in these cells (Klohs et
al., 1986; Assaraf et al., 1989).
Despite the theoretical advantages of TMQ versus metho-
texate and its promising preclinical activity, clinical trials
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with TMQ in colorectal carcinoma have shown disappointing
results. We therefore investigated the intrinsic determinants
of sensitivity to TMQ in two human colorectal carcinoma
cell lines with different sensitivity to TMQ-associated
lethality. Such studies may suggest new strategies designed to
overcome the intrinic resistance mechanisms to TMQ in colo-
rectal cancer.
Materials and methods
TMQ, 6-R,S-5-formyltetrahydrofolate (leucovorin), and [14C]-
TMQ monoisethioate (sp. act. 13 mCi mmol 1) were supplied
by the Drug Synthesis and Chemistry Branch, Developmental
Therapeutics Program, National Cancer Institute. The purity
of the [14C]TMQ was determined by high-performance liquid
chromatography (HPLC); virtually 100% of the counts
appeared in the fraction coeluting with TMQ standard.
[3',5'7-3H]methotrexate (sp. act. 20 Ci mmolP'), 6-1-[3',5',7-
3H]leucovorin (sp. act. 40 Cimmol '), [6-3H]dUrd (sp. act.
20 Ci mmol1'), [3',5',7,9-3H]folic acid (sp. act. 20 Ci mmoll')
and [5-3H]dUrd (sp. act. 15 Ci mmol-') were obtained from
Moravek Biochemicals (Brea, CA, USA). The radiopurity of
each compound as determined by HPLC was >98%. Sep-
pak C18 cartridges and Pic Reagent A were purchased from
Waters Chromatography Division of Millipore (Milford,
MA, USA). Other chemicals were supplied by either Sigma
(St. Louis, MO, USA), Aldrich Co. (Milwaukee, WI, USA)
or J.T. Baker (Phillipsburg, NJ, USA). Lactobacillus casei TS
(sp. act. = 5.4 x 109mol min-' mg-1) was from the New
England Enzyme Center (Boston, MA, USA). 5,10-Methy-
lene tetrahydrofolate was prepared as previously described
(Grem et al., 1989). Human DHFR purified from MCF-7
breast cancer cells was a generous gift from Dr Bernard
Kaufman (National Institute of Diabetes and-Digestive and
Kidney Diseases, Bethesda, MD, USA).
Cell culture
SNU-C4 and NCI-H630 cells are anchorage-dependent
human colorectal cancer cell lines (Park et al., 1987). Neither
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cell line has been selected for resistance to methotrexate or
TMQ. The cells were grown in 'complete medium' consisting
of RPMI-1640 medium supplemented with 7% non-dialysed
fetal bovine serum and 1.8 mM glutamine (Biofluids, Rock-
ville, MD, USA). Folate-free minimal essential medium was
purchased from Gibco (Grand Island, NY, USA). Cell
growth and colony formation were assessed as previously
described (Grem & Fischer, 1985; Grem & Allegra, 1990).
The amount ot tissue culture medium per cm2 of tissue
culture well or flask was constant for all experiments. For
each type of experiment, the starting cell density was similar
for both cell lines: 500 cells per 12.25cm2 for cloning
experiments and 2,000-4,000 cells percm2 for cell growth
and all other experiments.
TMQ uptake
Total cell-associated TMQ accumulation was determined ac-
cording to the method of Kamen et al. (1984). Exponentially
growing cells were exposed to [14C]TMQ (41AM) in folate-
depleted medium. After incubation times of 5-60min, the
cells were washed three times with iced phosphate-buffered
isotonic saline (PBS), and then were removed in 1 ml of
distilled water by a cell scraper; residual radioactivity was
quantitated in a liquid scintillation counter. Efflux was deter-
mined by incubating the cells with ['4C]TMQ for 30 min; the
cells were then washed once with iced PBS and incubated in
fresh folate-free medium. The cells were harvested at 5, 15,
30 and 60 min and the radioactivity was determined.
To determine intracellular accumulation and retention of
TMQ, cells were exposed to 1 fjM ['4C]TMQ in complete
medium for 24 h. The cells were washed twice in RPMI and
either harvested immediately or incubated in drug-free com-
plete medium for an additional 24 or 48 h. To harvest, the
cells were washed once with PBS, removed with a cell
scraper, collected by centrifugation at 240g, and frozen until
analysis. The pellet was sonicated in 300tlI of 50 mM
Tris-HCl (pH 7.4) containing 50 mM NADPH, and then
centrifuged at 8,000g for 45 min. The radioactivity in an
aliquot of the lysate was determined. Protein concentrations
were determined by the method of Bradford (1976).
Assay ofDHFR catalytic activity
Exponentially growing cells were washed once with PBS,
exposed to 20 mM EDTA (pH 7.5) for 20-30 s, then in-
cubated in PBS at 37°C until the cells detached. The dis-
lodged cells were washed once with ten volumes of iced PBS
and collected by centrifugation at 800g for 12 min. The cell
pellet was then frozen until the day of assay. The cells were
resuspended in 200-500ftl of 100 mM Tris-HCI buffer
(pH 7.5), sonicated and the cytosol isolated by centrifugation
as above. The catalytic activity of DHFR was quantitated
using [3H]dihydrofolate as the substrate (Dedhar et al., 1986).
[3H]Dihydrofolate was synthesised by dithionite reduction of
[3H]dihydrofolate and purified by recrystalisation according
to the method ofHayman et al. (1978). The reaction mixture,
in a total volume of 200fil, contained the following: 12.5 mM
Tris-HCI pH 7.5, 0.2 M potassium chloride, 0.8 mM NADPH
and 0.1 mM [3H]dihydrofolate. The reaction was started by
the addition of [3H]dihydrofolate at 37°C. The reaction was
quenched by placing the samples on ice and adding excess
unlabelled folic acid (25ftl of 27 mM). Unreduced dihydro-
folate and folic acid were precipitated by the addition of zinc
sulphate (30 gd of 170 mM) and glacial acetic acid (10JAl). The
sample was then centrifuged at 8,000g for 30 min at 4°C;
then the radioactivity in the supernatant minus the back-
ground was quantitated in a liquid scintillation counter. The
background was determined from a duplicate sample to
which no NADPH had been added. The reaction was linear
for at least 20 min. The IC50 of TMQ in the cytosolic assay
was determined by preincubating the NADPH mixture with
half-log increments ofdrug from 1nMto 10JAMfor 2 minat
room temperature before adding [3H]dihydrofolate.
To determine DHFR catalytic activity during and follow-
ing TMQ exposure, cells were washed once with iced PBS,
removed from the flask in iced PBS with a cell scraper and
centrifuged as above. To maintain the stability of the TMQ
bound to DHFR, the cell pellet was brought up in a total
volume of 250Jl of 50 mM Tris (pH 7.4) containing 0.5 mM
NADPH. Cytosol obtained from cells exposed to 500JAM
TMQ for I h provided the background counts.
Assay ofDHFR-binding capacity
The DHFR-binding assay was based on a modification of the
protein binding assay described by Myers et al. (1975). Each
250JLLI reaction mixture contained 100 mM Tris-HCI buffer
(pH 7.5), various concentrations of [3H]methotrexate,
0.22 mM NADPH and 0.2-0.5 mg of cytosolic protein. The
contents of the tubes were mixed and allowed to equilibrate
at room temperature for Omin; 50Jl of a charcoal slurry
(consisting of activated charcoal 10 g, bovine serum albumin
2.5 g, and 0.1 g of high molecular weight dextran in 100 ml
of water) was then added. The samples were immediately
mixed and centrifuged at 6,000 g for 30 min. A 150Jl aliquot
of the supernatant was counted in a scintillation counter.
Scatchard analysis was used to determine the dissociation
constant (Kd).
Preparation of the cell extract and the binding assay itself
were modified to permit quantitation of total DHFR binding
capacity following TMQ exposure. Following a 24h drug
exposure, the medium was aspirated and the cells were
washed three times with PBS. The cytosol was then obtained
as described above and dialysed at 4°C against 41 of 50 mM
Tris-HCI (pH 8.5) per day using a prepared dialysis memb-
rane (mol. wt. cut-off 6,000-8,000) and a microdialysis
system (Bethesda Research Laboratories, Gaithersburg, MD,
USA). The duration of dialysis was 24 h for 0.1 JAM TMQ
and 48 h for 1 JAM TMQ. An aliquot of the cytosol was
incubated with 300,000d.p.m. [3H]methotrexate and 100mM
Tris-HCI buffer (pH 7.5) for 3 h at 37°C. NADPH was then
added (final concentration 0.22 mM) and the samples were
allowed to equilibrate at room temperature for 10 min prior
to the addition of an activated charcoal slurry. The samples
were immediately vortexed and centrifuged at 6,000 g for
30 min; the radioactivity in an aliquot of the supernatant was
determined.
The extraction procedure was modified further for separate
experiments designed to measure the residual free DHFR
binding sites following TMQ exposure. After a 24 h exposure
to either diluent (dH2O) or TMQ (0.1 and 1.0JAM), the
medium was aspirated and the cells were washed once with
iced PBS. The cells were harvested at 48 and 72 h (24 and
48 h after removal of TMQ) as described above. The cell
pellet was resuspended in 250 l of 100 mM Tris-HCI
(pH 7.5) with NADPH (0.5 mM); after sonication, the lysate
was collected after centrifugation. Additional NADPH (final
concentration 1 mM) was directly added to the reaction mix-
ture containing cell lysate, 100,000 d.p.m. [3H]methotrexate,
100 mM Tris-HCI buffer, and the assay proceeded as pre-
viously outlined.
Measurement of[3H]methotrexate dissociation rate
The dissociation rate of [3H]methotrexate from DHFR in a
cell-free assay was determined by a modification of the
radioisotopic method described by Jackson et al. (1977).
Briefly, 50,000d.p.m. [3H]methotrexate (20;JCi nmol 1) was
added to a 5-fold excess of DHFR in the presence of
0.1 JAmol of NADPH and a physiological buffer (50mM
potassium phosphate pH 7.0, 50mM sodium chloride) in a
total reaction volume of 1 ml. The reaction was started by
adding a 100-fold molar excess of unlabelled TMQ. At
various intervals thereafter, 80 ll samples were taken and
free [3H]methotrexate was separated from that bound to
DHFR by adsorption with 20 ,ul of a dextran-albumin-
coated charcoal slurry and rapid filtration through a Gelman
0.45 ym Acrodisc (Potomac Scientific, Rockville, MD, USA)
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permitting measurement of the loss of bound [3H]metho-
trexate from DHFR over time.
Thymidylate synthase activity and binding
TS activity in an aliquot of cytosol was assayed by a
modification of a [5-3H]dUMP release assay (Yalowich &
Kalman, 1985; Roberts, 1966). dUMP pools were determined
with the same assay except that excess exogenous TS and
reduced folate were added, and the amount of dUMP was
the limiting substrate (Grem et al., 1989). The formation of a
ternary complex consisting of TS, 5,10-methylene tetrahydro-
folate and [6-3H]5-FdUMP was studied using a binding assay
(Moran et al., 1979; Allegra et al., 1986).
Measurement ofdeoxy- and ribonucleotide triphosphate pools
dTTP pools were monitored using a previously described
enzymatic assay (Grem & Fischer, 1985). ATP and GTP
pools were determined by anion-exchange HPLC as
previously described (Grem & Allegra, 1990).
Intracellularfolate pool measurements
Exponentially growing cells in folate-free medium supple-
mented with 0.1 LM d,l-leucovorin were exposed to [3H]-
leucovorin for a 72 h period, following which the cells were
washed twice with PBS. Fresh medium was replaced, and
then TMQ (1 gM) or dH2O was added for a 24 h period. The
cells were either harvested immediately or washed twice with
PBS and incubated in drug-free medium for an additional
24 h period. Folates were extracted, enzymatically hydrolysed
to monoglutamate forms, then separated and quantitated by
reversed-phase HPLC as previously described (McMartin et
al., 1981; Allegra et al., 1986; Baram et al., 1987).
pH step alkaline elution ofnascent DNA
Exponentially growing cells were exposed to either no drug
or 1 and 10tAM TMQ for 24 h; [3H]dThd (10fACi) was added
during the final 2 h of exposure. The cells were then washed
three times with ice-cold PBS, and the cells were detached by
incubation with 20 mM disodium EDTA (pH 7.0). An equal
number of cells was deposited on Nucleopore filters (25 mm,
1 lm pore size; Costar, Cambridge, MA, USA), held in an
alkaline elution funnel (Millipore), then lysed in the dark
with 5 ml of buffer containing 2 M sodium chloride, 0.3%
sarcosyl detergent (pH 7.0) and 20 mM dosodium EDTA,
pH 10.0 (Erickson et al., 1979; Ross et al., 1990). The lysed
cells were washed with 5 ml of 20 mM disodium EDTA
(pH 10) and then the exit tubing from the filter funnel was
connected to a peristaltic pump (Minipuls III; Gilson In-
strument, Middleton, WI, USA). A solution containing
20 mM EDTA (free acid form) adjusted to pH 11.3 with 1 M
tetrapropylammoniumhydroxide (RSA, Ardsley, NY, USA)
was added to the funnel and pumped through the filter at a
rate of 0.08 ml min-'. After 1 h, the solution was changed to
one at pH 11.5, and the elution was continued for another
hour. Fractions were collected with an automated fraction
collector. This procedure was repeated for successive elutions
at pH 11.7 and 12.1. The filter and elution fractions were
neutralised with 150 p1 ofglacial acetic acid; scintillation fluid
was added, and after a 24 h equilibration period the radio-
activity was determined. The data were corrected for back-
ground counts.
Cell cycle analysis
The method of Krishan (1975) was used to evaluate the
fraction of cells in each DNA cycle. Briefly, exponentially
growing cells were exposed to no drug or to 1 liM TMQ for
24 h, then were lysed in a hypotonic solution in dilute citric
acid. The nuclei were isolated, treated with DNAse-free
RNAse, stained with propidium iodide, and then passed
through a 35tLm nylon mesh. The cells were analysed on a
Beckton-Dickinson flow cytometer FACScan using CellFIT
software. The data were evaluated with the sum of broad-
ened rectangles model.
Western immunoblot analysis ofDHFR content
Equal amounts of cytosolic protein (200jg) from either con-
trol or TMQ-treated cells were resolved by sodium dodecyl
sulphate polyacrylamide gel electrophoresis using 15% acryl-
amide according to the method of Laemmli (1970). The gel
was electroblotted onto a nitrocellulose membrane using a
BioRad Transblot Semi-dry transfer cell with a Pharmacia
electrophoresis power supply set at 200 mA for 2 h. Antibody
staining was performed as described by Davis et al. (1986)
with a human DHFR polyclonal antiserum (1:1000 dilution
in Blotto buffer) that was obtained after serial i.v. injections
(150,lg) of human DHFR purified from MCF-7 human
breast cancer cells. A horseradish peroxidase-conjugated
antibody (1:1,000 dilution in Blotto buffer) was used as the
secondary antibody. Positive images were digitised by a Scan-
Jet Plus scanner (Hewlett Packard) and analysed by NIH
Image 1.36 software (Wayne Rasband, National Institute of
Mental Health, Bethesda, MD, USA).
Results
Comparison of TMQ-induced lethality
The doubling times during log-phase growth were similar:
18 h (C4 cells) and 22 h (H630 cells). After a 24 h exposure
to TMQ followed by a 48 h drug-free period, the IC50 values
for growth inhibition were 0.05 (C4) and 0.1ILM (H630),
respectively. A 24 h exposure to 0.1ILM TMQ, however,
decreased colony formation by only 20% in C4 cells and had
minimal effect in H630 cells (Figure 1). A 24 h exposure to
1I1AM and 1OIM TMQ reduced cell growth by 78% ±4%
and 84% ± 3% of control in C4 cells, and clonogenic
capacity was decreased by 42% and 50% respectively. In
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Figure 1 Effect of TMQ on clonogenic capacity. Exponentially
growing cells (500) were replicately plated in six-well plates. The
next day, varying concentrations of TMQ were added. Following
a 24 h exposure, the cells were gently washed twice and fresh
drug-free medium was replaced. Six days later, the cells were
stained with methylene blue (0.25%) in 50% methanol, and
colonies were enumerated. The data, presented as the
mean ± s.e.m. are from >4 separate experiments each done in
duplicate: V, C4; *, H630. The cloning efficiency ofcontrol cells
was as follows: C4, 51% ± 5%; H630, 31% ± 2%. Similar results
were obtained if a 2 day equilibrium period was allowed between
plating and initial drug exposure.1078 J.L. GREM et al.
H630 cells, a 24 h exposure to 1 and 1O lM TMQ reduced
cell growth by 66% ± 6% and 72% ± 4% respectively,
whereas colony formation was minimally affected. Concur-
rent exposure to 1 and 10gM verapamil did not affect TMQ
toxicity in either C4 or H630 cells. A 24 h exposure to TMQ
in medium supplemented with dialysed FBS increased the
toxicity; however, the H630 cells remained less sensitive than
C4 cells. For example, with 1 gM TMQ, the colony number
was reduced by 92% in C4 cells but only by 38% in H630
cells; 10 fLM TMQ reduced colony formation in H630 cells by
70%.
TMQ uptake and retention
During a 60 min exposure to 4tLM [14C]TMQ in a folate-
depleted medium, total cellular accumulation of TMQ occur-
red rapidly. An apparent plateau was reached by 30 min, and
was similar in both cell lines (mean + s.e.m., n = 4): C4,
276 ± 32 pmol 10-6 cells; H630, 250 ± 27 pmol 10-6 cells.
Following removal of ['4C]TMQ, efflux occurred rapidly, and
reached a plateau by 30 min, at which time the levels of
cell-associated TMQ were similar in both lines
(mean ± range: n = 2): C4, 30 ± 2 pmol 10-6 cells; H630,
32 ± 9 pmol 10-6 cells.
Because of the possibility that differences in TMQ accu-
mulation might occur following a more prolonged exposure,
['4C]TMQ retention was also determined following a 24 h
exposure (1 tM) in complete medium. Immediately after drug
removal, cytosolic TMQ was 2.5-fold higher in C4 than in
H630 cells (mean ± s.e.m. n = 8): 149 ± 8 vs 60 ± 4 pmol
mg-' protein (P<0.001, paired t-test). TMQ levels decreased
over the next 24 h in both cell lines, but remained 1.6-fold
higher in C4 cells: 13.4± 1.4 vs 8.6±0.7pmolmg-'
(P = 0.003). TMQ levels decreased only slightly thereafter
(72 h, 9.2 + 1.7 vs 8.5 ± 0.8 pmol mg-'). Differences in TMQ
retention after a 24 h exposure might therefore contribute to
the disparity in sensitivity between the C4 and H630 cells.
Activity ofdihydrofolate reductase and thymidylate synthase
The characteristics of DHFR in cell-free assays from non-
drug treated cells are shown in Table I. The [3H]metho-
trexate-binding capacity of DHFR, which provides an index
of DHFR content, was similar in the two cell lines. DHFR
catalytic activity was also similar. DHFR from both cell lines
was equally sensitive to TMQ-associated inhibition. The
specific activity of [14C]TMQ (13 mCimmolh-) was too low
to permit its use in Scatchard analysis experiments. The
calculated KD values determined with [3H]methotrexate, how-
ever, were not significantly different. The ability of cold
Table I Characteristics of dihydrofolate reductase and thymidylate
synthase
SNU-C4 NCI-H630
DHFR
Binding (pmol mg') 1.5 ± 0.2 1.0 ± 0.1
Catalytic activity (pmolmin-'mg ')
[3H]Dihydrofolate assay 1629 ± 250 1583 ± 176
Turnover (min') 1058 1599
ICs TMQ (nM) 28 ± 12 32 ± 10
KD (Scatchard analysis) 204 ± 75 331 ± 116
[3H]Methotrexate off-rate (min) 19 17
TS
Binding (pmol mg-') 42 ± 3 36± 8
Catalytic activity (nmol min-'mg ') 11.0 ± 1.3 6.9 ± 0.9
Turnover (min-') 262 192
The characteristics of DHFR and TS were determined as
referenced in the methods section. The DHFR data, presented as the
mean ± s.e.m., are from multiple separate experiments each assayed
in duplicate (C4 and H630 respectively): binding, n = 25 and 28;
catalytic, n = 18 and 23; Scatchard, n = 6 and 7; IC50 TMQ, n = 7
and 6; the [3H]methotrexate off-rate data are from one experiment
done in triplicate (ratio of unlabelled TMQ to methotrexate = 100:1).
The TS data, presented as the mean ± s.e.m. are from 5-6 separate
experiments each run in duplicate.
TMQ to displace [3H]methotrexate from DHFR (the 'off-
rate') was similar for the two cell lines. TS content and TS
catalytic activity were not significantly different in these two
lines.
Inhibition ofDHFR during TMQ exposure
Immediately following a 24 h exposure to 0.1I .M TMQ,
apparent free DHFR binding capacity was decreased in both
cell lines (Figure 2): C4, 0.39pmolmg-' (27% of control);
H630, 0.28 pmol mg-' (25% of control). Greater effects were
seen with I gM TMQ for 24 h: C4, 0.16 pmol mg-' (11% of
control); H630, 0.10 pmol mg-' (9% of control). The appar-
ent values of unbound DHFR in this cell-free assay may
overestimate the free binding sites in situ as a result of
displacement of TMQ from DHFR during processing. While
some displacement of TMQ during cell processing is un-
avoidable, we attempted to minimise this problem. Cells from
both lines were harvested quickly in a uniform manner with
minimal washing. NADPH was added to the cell pellet prior
to sonication to promote stability of the TMQ-DHFR com-
plex. The cell pellets were reconstituted with a uniform
volume of buffer; finally, the cytosol was allowed to equili-
brate with [3H]methotrexate for only 10 min before the addi-
tion of charcoal to remove unbound [3H]methotrexate.
Complementary studies revealed that DHFR catalytic
activity was reduced to 26% and 46% of control in C4 and
H630 cells, respectively, after a 24 h exposure to 0.1 AM
TMQ (Figure 3). Exposure to higher concentrations of TMQ
() 1 LM) resulted in greater inhibition of DHFR catalytic
activity to < 15% of control in both cell lines. Thus, similar
inhibition of DHFR was achieved during TMQ exposure in
both cell lines as reflected by both the degree of occupied
binding sites and greatly diminished catalytic activity.
Recovery ofcatalytically active DHFRfollowving TMQ
exposure
Although DHFR inhibition in C4 and H630 cells was similar
during drug exposure, we wished to test the possibility that
the duration of DHFR inhibition might be different after
drug removal. The apparent free DHFR binding sites in-
1.4
1.2
'c, 1.0
E
E 0.8
IL U-
I 0.6
0
E 0.4
0.2
0.0
24 48 72
Time (h)
Figure 2 Recovery of apparent free DHFR binding sites follow-
ing TMQ exposure. C4 (V, V) and H630 (0, *) cells were
exposed to 0.1 M (open symbols) or 1.0gM TMQ (closed sym-
bols) for 24 h. The cells were harvested either immediately or 24 h
and 48 h following drug removal. The cytosol was then isolated
and the amount of apparent unbound DHFR binding sites was
estimated by a competitive binding assay. The data, presented as
pmol of [3H]methotrexate bound per mg protein (mean ± s.e.m.)
are from 4-11 separate experiments each run in duplicate.DETERMINANTS OF TRIMETREXATE LETHALITY 1079
creased 1.7-fold in C4 cells and 3.9-fold in H630 cells (to
46% and 100% of control, respectively, 48 h after removal of
0.1I tLm TMQ; Figure 2). Following 1.0J.Lm TMQ, however,
the apparent free DHFR binding sites increased by only
1.4-fold and 2.7-fold in C4 cells at 48 h and 72 h to 16% and
30% of control respectively. In H630 cells, in contrast, the
apparent free DHFR binding capacity increased by 4.2-fold
and 10.4-fold at 48 h and 72 h to 38% and 95% of control
respectively. Thus, recovery of free DHFR binding sites
appeared to be essentially complete 48 h following removal
of 0.1~I m and I JAm TMQ in the H630 cells.
Partial to complete recovery of DHFR catalytic activity
was evident in both lines 48 h after removal of 0.1 JAm TMQ
(Figure 3). With , 1 JAm TMQ, persistent inhibition of
DHFR was evident in C4 cells for up to 48 h post washout
of TMQ. Further, DHFR remained inhibited after 100 JAm
TMQ (catalytic activity <10% of control), a concentration
associated with complete lethality. In contrast, H630 cells
had essentially complete recovery of DHFR catalytic activity
48 h following 1 JAm and 10 JAm TMQ (to 96% and 75% of
control respectively). With 100 and 500JAm TMQ, however,
persistent inhibition of DHFR catalytic activity (,< 18% of
control) was noted. The results suggest that, although DHFR
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inhibition during drug exposure was accompanied by growth
inhibition, it did not closely correlate with lethality. In con-
trast, DHFR catalytic activity 48 h after TMQ exposure
appeared to be a more accurate predictor for lethality in C4
and H630 cells (Figure 4).
We wished to verify the duration of DHFR inhibition in
intact cells. Pulse incorporation of [6-3H]dUrd into acid
precipitable material provides an index of TS activity, and is
affected by the availability of 5,10O-methylenetrahydrofolate
through the DHFR pathway. Since exposure to TMQ may
result in dUMP accumulation, we measured the total endo-
genous dUMP pools following TMQ exposure to correct for
dilution of [3H]dUMP. Baseline dUMP pools were 1.9-fold
higher in C4 cells (1513 ± 318 vs 813 ± 127 pmol 10-6 cells in
H630 cells). Following 0.1IJAm TMQ, dUMP pools were
elevated 1.4-to 4.5-fold over baseline, and returned to
baseline by 72 h (48 h following drug removal) in both cell
lines. With 1.0 JAm TMQ, however, persistent elevation of
dUMP was noted for up to 72 h in both cell lines; the
absolute dUMP levels were about 2-fold higher in C4 cells at
each time point.
A 24 h exposure to 0.IJgm TMQ decreased [3H]dUrd
incorporation to 44% and 17% of control in H630 and C4
cells respectively (Table II). Immediately following a 24 h
exposure to 1.0 Jm TMQ, more pronounced inhibition was
seen in both cell lines. In C4 cells, [3H]dUrd incorporation
remained <20% of control at 48 h and 72 h (24 and 48 h
following TMQ removal), while partial recovery occurred in
H630 cells (H630 vs C4 at 48 h, P = 0.02).
As another indirect measure of DHFR activity, we deter-
mined the effect of a 24 h exposure to 1.0 lam TMQ on the
intracellular folate pools in cells prelabelled with
[3H]leucovorin. Immediately following a 24 h TMQ exposure,
[3H]dihydrofolate was detected in both C4 and H630 cells,
whereas none was detected in control cells (Table III). Fol-
lowing washout of TMQ and [3H]leucovorin, the tritium in
the total intracellular folate pool decreased over time,
presumably as a result of exchange and dilutional effects
resulting from continued cellular metabolism and effiux. The
percent decrease in 3H in the total intracellular folate pool
serves as an index of the decrement expected from these
effects. In both cell lines, the total radiolabelled intracellular
folate poo1 decreased by 38-50% over the ensuing 24 h
period in both control and TMQ-treated cells. In C4 cells,
the [3H]dihydrofolate pool decreased by essentially the same
proportion (55%), consistent with continued inhibition of
a
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Figure 3 Recovery of DHFR catalytic activity following TMQ
exposure. Exponentially growing cells were exposed to various
concentrations of TMQ for 24 h (0, 0.1I Lm; V, I gLm; 0, 10jim;
'0, 100 Jim; A, 500 Jum) then were either harvested immediately
or gently washed and incubated in drug-free medium. The cell
pellets were frozen until analysis; the pellets were the resuspended
in 50 mmv Tris-HCI buffer (pH 7.4) containin'g 0.5 mmv NADPH,
and the cytosol was isolated by centrifugation after sonication.
DHFR catalytic activity was determined by measuring the con-
cersion of [3H]dihydrofolate to [3H]reduced folates as described in
Materials and methods. The data for drug-treated cells are shown
as the percentage control DHFR catalytic activity
(mean ± s.em.), and are from 4-8 separate determinations at
each TMQ concentration: the activity in control cells was as
follows (pmol mmn- mg-'): C4, 1,629 ± 250; H630,
1,583 ± 170.
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Figure 4 Relationship of DHFR catalytic activity 48 h post
removal of TMQ and clonogenic survival. DHFR catalytic
activity 48 h following removal of TMQ as a percentage of
control is plotted against the viability (per cent control); U,
H630; V, C4. The r2 value for the linear regression was 0.91.
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Table 11 Effect of TMQ on [3H]dUrd incorporation into DNA
% control [3H]dUrd
incorporation
Condition SNU-C4 (%) NCI-H630 (%)
0.1IJM TMQ
24h 17 5 43±4
48 h (24 h post drug removal) 31 23 118 ±45
72 h (48 h post drug removal) 35 ± 14 67 ± 14
1.0 M TMQ
24h 10±4 13±7
48 h (24 h post drug removal) 10 7 60 22
72 h (48 h post drug removal) 18 ± 6 48 ± 9
Exponentially growing cells were exposed to 0.1 jAM or 1.0gM
TMQ for 24 h, following which the cells were either harvested or
gently washed free of drug and placed in drug-free medium. At the
desired interval, cells were pulse labelled with [6-3H]dUrd and the
incorporation into acid-precipitable material was determined. The
data, shown as mean ± s.e.m. are from 4-8 separate experiments
each done in duplicate. The endogenous dUMP levels in control and
TMQ-treated cells were determined (n > 4 experiments) with a
modified tritium-release assay using [5-3H]dUMP, and were then
used to correct for differences in cold dUMP pools in drug-treated
cells (data not shown). dUMP pools in control cells were as follows
(pmol 10-6 cells, mean ± s.e.m.): C4, 1513 ± 318; H630, 813 ± 127.
Table III Effect of TMQ on [3H[dihydrofolate metabolism in intact
cells
Total intracellular
Cell line Condition Dihydrofolate [3H]folate pool
SNU-C4 Control
24h 0 17.9±4.8
48 h 0 10.5 3.1 (59%)
I JM TMQ
24h 2.2 1.0 22.4 5.9
48 h 1.0 0.3 (45%) 11.2 ±4.7 (50%)
NCI-H630 Control
24h 0 18.9±7.4
48h 0 11.8 3.9 (62%)
1 JiM TMQ
24h 6.4±4.0 23.2 5.8
48 h 1.4 1.5 (22%) 14.6 5.8 (63%)
Exponentially growing cells in folate-free medium supplemented
with 0.1IJM leucovorin were prelabelled with [3H]leucovorin for 72 h,
following which the cells were gently washed and then exposed to
dH20 or 1.0JIM TMQ for 24 h. Either immediately after the drug
exposure or 24 h following washout of TMQ, cells were extracted as
described in the Materials and methods section. After enzymatic
hydrolysis of the polyglutamated residues, the [3H]folate pools were
determined by reversed-phase HPLC. The data, presented as pmol
folate per mg protein (mean ± s.d.), are from three separate
experiments. The size of the folate pool at 48 h as a percentage of
the folate pool at 24 h is shown in parentheses.
DHFR. In the H630 cells, in contrast, the decline in the
[3H]dihydrofolate pool, 78%, appeared to be greater than
expected on the basis of exchange and dilutional effects,
consistent with partial recovery of DHFR and resumption of
dihydrofolate utilization.
Effect of TMQ exposure on total DHFR content
To test the hypothesis that total DHFR content may change
following a 24 h TMQ exposure, cytosol obtained from con-
trol and drug-treated cells was extensively dialysed to remove
free TMQ and drug bound to DHFR. A longer (3 h) incuba-
tion with [3H]methotrexate was also used to permit complete
exchange with any residual bound TMQ. The adequacy of
dialysis was assessed by comparing the DHFR binding
capacity of cells harvested immediately after 1 h exposure to
TMQ with control values. We reasoned that a 1 h exposure
would be too brief to result in changes in total levels of
DHFR; therefore, if DHFR levels measured after a 1 h drug
exposure were similar to control levels, the dialysis was
assumed to be complete. After a 24 h and 48 h period of
dialysis, the DHFR binding capacity in cytosols from cells
exposed for 1 h to 0.1 and 1.0 JiM TMQ, respectively, was
1.2-fold (± 0.1) of control values in both cell lines, indicating
that essentially all TMQ had been removed from DHFR.
Immediately after a 24 h exposure to 0.1IJM TMQ, however,
an increase in total DHFR binding over baseline was evident
in both lines (pmol mg-'): C4, 3.3 ± 0.6 (n = 6) vs 1.7 0.2
(n = 16, P= 0.004); H630, 3.1 ± 0.4 (n = 9) vs 0.9 0.1
(n = 14, P<0.001). With 1 JAM TMQ, no increase in DHFR
binding capacity was seen in C4 cells (1.8 ± 0.3 pmolmg-',
n = 8). A 2.2-fold increase over baseline DHFR binding
occurred, however, in H630 cells: 2.0 ± 0.2 pmol mg-' (n = 6,
P>0.001). With 10 JAM TMQ, removal of bound drug was
incomplete after 72 h of dialysis. Prolonged dialysis beyond
72 h resulted in progressive loss of enzymatic activity;
therefore, experiments using higher concentrations could not
be reliably interpreted using the binding assay.
Because DHFR content may vary in different phases of the
cell cycle, it was important to ascertain the effect ofTMQ on
cell cycle distribution. The proportion of control cells in
S-phase was similar in both cell lines (C4, 45% ± 17%; H630
cells, 48% ± 14%, mean ± s.d., n = 3). A 24 h exposure to
1 JAM TMQ was associated with an 11-12% increase in the
proportion of cells in S-phase in both cell lines (C4,
56% ± 36%; H630, 60% ± 24%). No change was seen in the
proportion of cells in Go/G1. TMQ exposure was accom-
panied by a block in the entry of cells into G2/M phase
(control vs TMQ-treated, mean ± s.d.): C4, 11% ± 2% vs
0.7% ± 0.7%; H630, 12% ± 1% vs 0.6% ± 0.1%. Thus, 1 JM
TMQ produced comparable effects on the cell cycle in each
cell line.
An increase in DHFR protein levels was confirmed by
Western immunoblot analysis in H630 cells treated with 1 JiM
TMQ for 24 h (Figure 5), whereas no appreciable change was
evident in C4 cells. To determine whether new protein syn-
thesis contributed to this phenomenon, the effect of a 24 h
exposure to cycloheximide (CHEX) on [35S]methionine incor-
poration into acid-precipitable material was determined.
Then, the effect of concurrent exposure to CHEX and TMQ
was investigated. A 24 h exposure to CHEX with 1 JiM TMQ
attenuated the TMQ-associated increase in DHFR content in
a dose-dependent fashion (fold increase in DHFR densito-
metry signal relative to control): TMQ alone, 2.5-fold;
TMQ + 5 JAM CHEX (which inhibited protein synthesis by
40%), 1.7-fold; TMQ + 50 JAM CHEX (which inhibited pro-
tein synthesis by 79%), 1.2-fold. DHFR content in H630
cells remained 2.4- to 2.8-fold higher relative to control for
NCI-H630
A B C D F F kDa
39-
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Figure 5 Western immunoblot analysis of DHFR content fol-
lowing TMQ exposure in H630 cells. Equal amounts of cytosolic
protein (200 JAg) from control or TMQ-treated cells (1 JM for
24 h) were resolved by SDS-polyacrylamide gel electrophoresis
(15% acrylamide). A human DHFR polyclonal antiserum with a
horse radish peroxidase-conjugated antibody as the secondary
antibody was used to detect the DHFR protein. The contents of
the lanes are as follows (relative densitometry units are shown in
parentheses): A, protein molecular weight markers; B, purified
human DHFR; C and D, control (0.057 and 0.029 U); E and F,
TMQ-treated cells (0.131 and 0.123 U).DETERMINANTS OF TRIMETREXATE LETHALITY 1081
up to 48 h after removal of 1 tLM TMQ (data not
shown).
Effect of TMQ on dTTP and RTPpools
The magnitude ofdTTP depletion following antifol treatment
might be influenced by the degree of TS inhibition and the
contribution of dThd salvage. Following a 24 h exposure to
1.0 iM TMQ, dTTP pools were similarly decreased to 26%
and 17% of control in each line (Table IV). More pro-
nounced dTTP depletion (, 10% of control) was seen with
10pM TMQ in both lines. Dose-dependent decreases in ATP
and GTP pools were evident in both cell lines after a 24 h
drug exposure (Table IV). The magnitude of the effect was
similar in both cell lines.
The ability of intact cells to salvage dThd and purines was
then ascertained by measuring nucleotide formation (by
HPLC analysis of methanol-soluble cell extracts) and mac-
romolecular incorporation (methanol-precipitable fraction)
after a 1 h incubation with 1 JiM [3H]dThd or [3H]hypox-
anthine. dThd salvage (pmol 10-6 cells h-') was 45.4 ± 1.4 in
H630 cells (mean + s.d., n = 3), and was 1.9-fold higher in
C4 cells: 86.7 ± 0.9. Hypoxanthine salvage (pmol 10-6
cells h-') was 1,695 ± 65 in H630 cells, and 1,168 ± 55 in C4
cells. These data indicate that both cell lines were capable of
salvaging preformed dThd and purine bases.
Effect ofTMQ on nascent DNA synthesis
pH step alkaline elution was used to assess the effect ofTMQ
on newly synthesised DNA. In the pH transition zone,
molecular weight influences the selective denaturation of
newly replicated DNA exposed to alkali (Erickson et al.,
1979; Ross et al., 1990). Therefore, stepwise elution of DNA
with an alkaline solution at pH values ranging from 11.3 to
12.1 may show relative differences in the single strand length
of newly synthesised DNA. The proportion of single-strand
DNA species eluting with the 11.3-11.7 fractions in control
C4 and H630 cells was similar (about 7%), as was the
proportion of high molecular weight DNA retained on the
polycarbonate filter (about 50%, Figure 6). A 24 h exposure
to TMQ altered the elution profile in both cell lines: an
accumulation of lower molecular weight DNA species was
noted, accompanied by a decreased proportion of DNA
retained on the filter. These results suggest either interference
with DNA chain elongation during drug exposure or induc-
tion of DNA single-strand breaks associated with substrate
(dTTP) depletion and/or excision of deoxyuridine triphos-
phate by DNA repair enzymes. The abnormalities were more
striking in C4 cells: 47-54% of the DNA eluted with or
before the pH 11.7 solution in cells exposed to 1 and 10jiM
Table IV Effect of trimetrexate on dTTP and RTP pools
dTTP (pmol ATP (nmol GTP (nmol
Cell line 10-6 cells) 10-6 cells) 10-6 cells)
SNU-C4
Control 189 ± 27 36 ± 5 5.2 + 0.7
1 1M TMQ 32±5* (17%) 11±7* (31%) 2.6±0.4* (50%)
10gM TMQ 9 1* (5%) 9 1* (26%) 0.9±0.1* (17%)
NCI-H630
Control 129 32 21 6 3.4 1.0
I gM TMQ 33 ± 13* (26%) 9 ± 6 (45%) 0.8 ± 0.5* (24%)
10pM TMQ 13±4* (10%) 7 1* (34%) 0.6±0.1* (18%)
Exponentially growing cells were exposed to either no drug, 1.0 iLM
TMQ or 1OjiM TMQ for 24 h. The cells were then extracted with
0.5 N PCA, neutralized and then lyophilised. dTTP pools were
measured by a DNA polymerase assay, and ATP and GTP pools
were determined by anion exchange HPLC. The dTTP data are
presented as mean ± s.e.m. (control, n = 10) or s.d. (TMQ-treated
cells, n = 3). The ATP and GTP data for the controls, presented as
the mean ± s.d. are from three separate experiments each done in
duplicate, while the data for the TMQ-treated cells, presented as the
mean ± range, are from two separate determinations. The change in
nucleotide pools as percentage control is shown in parentheses;
*P<0.05 (t-test).
TMQ, compared with 19-26% in H630 cells; further, only
10% of the DNA was retained on the filter in C4 cells
compared to 22-26% in H630 cells. These data indicate that
the extent of damage and/or interference with elongation of
newly synthesised DNA was greater in the more sensitive C4
cell line.
Discussion
We found a disparity between sensitivity to TMQ-associated
lethality in two human colon cancer cell lines which had not
been selected for antifol resistance. Previously described
mechanisms of antifol resistance did not appear to account
for the relative insensitivity of H630 cells. DHFR and TS in
non-drug-treated cells were quantitatively and qualitatively
similar in both cell lines. TMQ does not require the reduced
folate transport mechanism for cell uptake, nor does it
undergo polyglutamation. Some cancer cells expressing the
MDR phenotype are cross-resistant to TMQ; decreased accu-
mulation of TMQ has been noted during brief (1-2 h)
incubations (Klohs et al., 1986; Assaraf et al., 1989).
Verapamil increased TMQ cytotoxicity in these MDR cells.
Single-step selection of mammalian cells with TMQ revealed
that the majority of the clonal variants displayed cross-
resistance to other lipophilic antifols; although this resistance
was not related to the MDR phenotype, decreased TMQ
accumulation was evident and low concentrations of vera-
pamil potentiated TMQ cytotoxicity (Sharma et al., 1991).
These mechanisms would not seem to apply to H630 cells,
since verapamil did not enhance TMQ toxicity. The capacity
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Figure 6 Effect on TMQ on newly synthesised DNA with pH
step alkaline elution. Exponentially growing cells were exposed to
either no drug (LII) 1IgM (X) or 10IgM (X) TMQ for
24 h; the cells were pulsed with 10 Ci of [3H]dThd for the last
2 h. The cells were harvested and lysed on a polycarbonate filter
as described in the Materials and methods section, and the
elution profile was determined by pH step alkaline elution. The
data are presented as the percentage of the total radioactive
counts eluting with each pH step (mean ± s.e.m.), and represent
the average of four separate experiments.
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of both cell lines to salvage dThd and hypoxanthine was of
similar magnitude. During a 24 h exposure to 1.0 and 10 J.M
TMQ, both lines showed similar DHFR inhibition as evi-
denced by significantly decreased DHFR catalytic activity,
greatly diminished availability of apparent free DHFR as
measured by [3H]methotrexate binding, depletion of dTTP,
ATP and GTP pools and inhibition of [6-3H]dUrd incorpora-
tion into DNA. Both cell lines demonstrated partial or com-
plete recovery of DHFR catalytic activity and apparent free
DHFR binding sites 48 h following washout of 0.1 LM TMQ,
which is growth inhibitory but non-lethal. DHFR recovered
towards normal in H630 cells 24-48 h after removal of 1 liM
TMQ (24 h), whereas C4 cells showed persistent inhibition of
DHFR. The extent of DHFR inhibition 48 h after TMQ
exposure was inversely related with viability, suggesting that
the duration of DHFR inhibition in these two cell lines was a
more important discriminant of TMQ-associated lethality
than the initial extent of DHFR inhibition.
The difference in sensitivity to TMQ and ability to recover
functional DHFR appears to be multifactorial. The extent of
interference with nascent DNA synthesis and/or DNA
damage was greater in the more sensitive C4 cell line, which
in turn may diminish its capacity to recover from the toxic
insult. Since dTTP depletion was similar in both cell lines,
other factors, perhaps the extent of dUTP incorporation into
DNA or altered activity of repair enzymes such as uracil-
DNA glycosylase, might be involved. These possibilities will
be the focus of future experiments.
Following a 24 h exposure to 1 ZlM, TMQ levels in cell
extracts immediately after drug washout greatly exceeded
DHFR content: the ratio of ['4C]TMQ to total DHFR was
82:1 and 30:1 in C4 and H630 cells, respectively. Over the
ensuing 48 h, ['4C]TMQ levels decreased by about one order
or magnitude, but still exceeded DHFR content by several-
fold. Nonetheless, free binding sites became available
24-48 h after drug removal in H630 cells, accompanied by
recovery of catalytic capacity. The retained drug is
presumably bound to other proteins and free drug is either
unavailable or inadequate to fully compete with the expand-
ed dihydrofolate pool for binding to unbound DHFR. The
basis for decreased cytosolic retention of TMQ in H630 cells
after a 24 h exposure is not clear. Fry and Besserer (1988)
previously reported both an intracellular exchangeable pool
of TMQ that was always several-fold higher than the extra-
cellular concentration and a large non-exchangeable fraction
of TMQ after drug removal that exceeded the DHFR-bind-
ing capacity in human lymphoblastoid cells. Decreased
accumulation or retention of lipophilic antifols might con-
ceivably result from changes in TMQ binding to proteins
other than DHFR or to other macromolecules by a process
that is unaffected by verapamil (Assaraf & Slotky, 1993).
H630 cells have the ability to increase thymidylate synthase
protein synthesis during fluorouracil exposure, which permits
recovery of TS catalytic activity (Chu et al., 1993). Abroga-
tion of the increase in thymidylate synthase content by
interferon y enhanced sensitivity to fluorouracil (Chu et al.,
1990). Swain et al. (1989) reported that the total amount of
thymidylate synthase in breast tumour specimens increased
by 2.6-fold 24 h following bolus fluorouracil administration.
Our results suggest that a phenomenon of similar magnitude
occurs with DHFR following 0.1 #LM TMQ in both cell lines
and with 1 pM TMQ in H630 cells. Other investigators have
reported that exposure of cancer cells to methotrexate may
be accompanied by acute increases in the cellular DHFR
content in a time- and concentration-dependent fashion
(Domin et al., 1982; Bastow et al., 1984; Cowan et al., 1986;
Bertino et al., 1962, 1963). The apparent basis for the in-
crease in DHFR content has varied depending on the cell
line or model system used. The experimental evidence sug-
gests multiple possible mechanisms including stabilisation of
DHFR by methotrexate accompanied by an increased intra-
cellular half-life, and methotrexate-dependent alterations in
DHFR content at both the transcriptional and post-tran-
scriptional or translational level. Chu et al. (1993) have
recently reported that, in a cell-free system, DHFR protein
specifically binds to DHFR mRNA and inhibits translation;
the addition of methotrexate prevented the binding of DHFR
protein to its mRNA, allowing translation to proceed. Thus,
DHFR appears to be capable of translational autoregulation
in a cell-free system. In intact cells, the factors governing
regulation of DHFR expression are undoubtedly more com-
plex. In a methotrexate-resistant subline of human KB cells
which have a stable 40-fold amplification of DHFR, Domin
et al., (1982) reported that an additional increase (up to
4-fold) in DHFR content occurred after a 48 h exposure to
various concentrations of methotrexate. A growth-inhibitory
but non-lethal TMQ exposure (0.1 JIM x 24 h) was accom-
panied by a 1.9-and 3.4-fold increase in total DHFR in C4
and H630 cells respectively. With 1 JiM, however, DHFR
content increased only in H630 cells. The observation that
cycloheximide attenuated the TMQ-associated increase in
DHFR signal suggests that new protein synthesis contributes
to this increase. The reasons for this differential capacity to
increase DHFR content with increasing TMQ concentrations
in these two cell lines are not yet understood. Other factors,
perhaps the extent of DNA damage, might indirectly affect
the capacity of the cell to increase DHFR.
In summary, the relative insensitivity to TMQ-mediated
lethality in H630 cells compared with C4 cells appears to be
related to greater recovery of DHFR activity after drug
removal. Recovery of functional DHFR may result from
several factors, including less DNA damage, reduced
cytosolic TMQ levels after a 24 h exposure and an increase in
total DHFR content. The underlying basis for the difference
in DNA damage during drug exposure in C4 and H630 cells
will require additional study. Finally, our data suggest that
prolonged exposure to TMQ may represent a potential
strategy to increase its cytotoxicity. Preliminary data from
our laboratory suggests that extending the duration of TMQ
exposure to 72 h increases the sensitivity of H630 cells to
TMQ. Further investigation will be required to characterise
more fully the effect of TMQ and other antifols on DHFR
content in H630 cells and other cell lines, and to elucidate the
factors governing regulation of DHFR expression.
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